AstraZeneca To Break Ground In Russia As MNCs Build Stronger Base In The Country
This article was originally published in PharmAsia News
Executive Summary
Scheduled to break ground in April, AstraZeneca PLC's investment of more than $150 million into construction of a drug manufacturing plant in Russia indicates the U.K.-based firm's confidence and long-term commitment to the emerging Russian market
You may also be interested in...
No Surprise AstraZeneca Singles Out Emerging Markets For Growth, But Japan Too?
Japan offers AstraZeneca a patent expiry cushion as the company tries to right itself elsewhere.
Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
Like many of its competitors, Sanofi SA considers emerging markets to be its number one growth driver, as the French drug maker transforms itself from a blockbuster-dependent model to a more balanced business with less risk. The goal is to deliver sustainable continuous revenues and profits, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts
Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
Like many of its competitors, Sanofi SA considers emerging markets to be its number one growth driver, as the French drug maker transforms itself from a blockbuster-dependent model to a more balanced business with less risk. The goal is to deliver sustainable continuous revenues and profits, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts